Analyst outperform ratings on Crispr stocks.

in #crispr • 8 years ago

Cowen, Barclays and ROTH all host healthcare conferences next week;

• Intellia Therapeutics (NASDAQ:NTLA) initiated with Outperform rating and $76 (158% upside) price target at JMP Securities.

• CRISPR Therapeutics (NASDAQ:CRSP) initiated with Outperform rating and $69 (34% upside) price target at JMP.


With this, I’ll likely hold my Crispr theme options (EDIT and NTLA) for a medium/long term instead. 

#stock #trading #ntla
8 years ago in #crispr by
$0.00
    Reply 0

    Coin Marketplace

    STEEM 0.06
    TRX 0.31
    JST 0.061
    BTC 69150.03
    ETH 2108.92
    USDT 1.00
    SBD 0.50